16-亚甲基雌二醇 | 7627-87-4

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 类固醇和类固醇衍生物
• 中文名称: 16-亚甲基雌二醇
• 中文别名: S,S-二丙基甲基磷羧基二硫酸酯
• 英文名称: 16-Methylenestradiol
• 英文别名: 16-methylen-estra-1,3,5(10)-triene-3,17β-diol；16-Methylen-oestra-1,3,5(10)-trien-3,17β-diol；16-Methylene estradiol；(8R,9S,13S,14S,17S)-13-methyl-16-methylidene-7,8,9,11,12,14,15,17-octahydro-6H-cyclopenta[a]phenanthrene-3,17-diol
• CAS: 7627-87-4
• 化学式: C₁₉H₂₄O₂
• 分子量: 284.398
• InChiKey: DJEKMVJLSAUQAO-GFEQUFNTSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.7
• 重原子数：
  21
• 可旋转键数：
  0
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.58
• 拓扑面积：
  40.5
• 氢给体数：
  2
• 氢受体数：
  2

反应信息

• 作为产物：
  描述：

  3-O-acetyl-16-methylene-estrone 在 四氢吡咯 、 sodium tetrahydroborate 作用下， 以 四氢呋喃 、 乙醇 为溶剂， 反应 48.0h， 生成 16-亚甲基雌二醇
  参考文献：
  名称：

  Synthesis of some analogs of estradiol

  摘要：

  As part of a search for estradiol derivatives designed for conjugation to carboxyl or amine functions of anti-cancer agents or suitable derivatives thereof, estradiol analogs with side chains at the C-16 or -17 position were prepared for biological assay. These analogs include several which have a substituted nitrogenous function at C-17. The avidity of some of these analogs for binding to estrogen receptor was found to be of a low order.

  DOI：

  10.1016/0039-128x(85)90037-6

文献信息

• New 2-substituted estra-1,3,5(10)-trien-17-ones as inhibitors of 17beta-hydroxy steroid dehydrogenase type 1
  申请人：Hillisch Alexander

  公开号：US20060009434A1

  公开（公告）日：2006-01-12

  The invention relates to new 2-substituted estra-1,3,5(10)-trien-17-ones of general formula I in which R 2 means a saturated or unsaturated C 1 -C 8 -alkyl group, a C 1 -C 5 -alkyloxy group, an aralkyl radical or alkylaryl radical, a radical —O—C n F m H o , whereby n=1, 2, 3, 4, 5 or 6, m≧1 and m+o=2n+1, or a group CH 2 XY, in which X stands for an oxygen atom and Y stands for an alkyl radical with 1 to 4 carbon atoms, as well as a halogen atom or a nitrile group, R 13 means a hydrogen atom or a methyl group, R 16 means a hydrogen atom or a fluorine atom, Z means an oxygen atom or a sulfur atom, R 3 and R 5 , in each case independently of one another, mean an α- or β-position hydrogen atom, R 4 and R 6 , in each case independently of one another, mean an α- or β-position hydrogen atom, a C 1 -C 5 -alkyl group, a C 1 -C 5 -alkyloxy group, a C 1 -C 5 -acyl group or a hydroxy group or an aralkyl radical or alkylaryl radical, R 3 and R 4 together mean an oxygen atom, R 5 and R 6 together mean an oxygen atom, R 7 and R 8 in each case mean a hydrogen atom or together a CH 2 group, as well as their pharmaceutically acceptable salts, their manufacture and use as medicaments for prophylaxis and therapy of estrogen-dependent diseases that can be influenced by the inhibition of 17β-hydroxy steroid dehydrogenase type 1.

  本发明涉及一般式I的新2-取代的酮类化合物，其中R2代表饱和或不饱和的C1-C8烷基基团，C1-C5烷氧基团，芳基烷基基团或烷基芳基基团，基团—O—CnFmHo，其中n=1、2、3、4、5或6，m≥1且m+o=2n+1，或基团CH2XY，其中X代表氧原子，Y代表具有1至4个碳原子的烷基基团，以及卤原子或腈基团，R13代表氢原子或甲基基团，R16代表氢原子或氟原子，Z代表氧原子或硫原子，R3和R5分别独立地表示α或β位的氢原子，R4和R6分别独立地表示α或β位的氢原子，C1-C5烷基基团，C1-C5烷氧基团，C1-C5酰基团，羟基或芳基烷基基团或烷基芳基基团，R3和R4一起表示氧原子，R5和R6一起表示氧原子，R7和R8分别表示氢原子或一起表示一个CH2基团，以及它们的药学上可接受的盐，它们的制备和用作预防和治疗由于17β-羟基类固醇脱氢酶类型1的抑制而可影响的雌激素依赖性疾病的药物。
• Compound
  申请人：Vicker Nigel

  公开号：US20060074060A1

  公开（公告）日：2006-04-06

  There is provided a compound of Formula (I) wherein (I) R2 is selected from (i) an alkyloxyalkyl group (ii) a nitrile group, and wherein R2 is capable of forming a hydrogen bond (iii) alkylaryl group, wherein the aryl group is substituted by other than a C1-10 group (iv) alkenylaryl group wherein the aryl group is substituted (v) alkylheteroaryl group, wherein when heteroaryl group comprises only C and N in the ring, the aryl group is substituted by other than a methyl group (vi) alkenylheteroaryl group, (vii) ═N—O-alkyl or ═N—O—H group (viii) branched alkenyl (ix) alkyl-alcohol group (x) amide or alkylamide wherein (a) the alkyl of the alkylamide is —CH2— or —Ch2Ch2—, (b) the amide is di-substituted and/or (c) the amide is substituted with at least one of alkyl heterocycle group, alkenyl heterocycle group, alkylheteroaryl group, alkenylheteroaryl group, heteroaryl group, alkylamine group, alkyloxyalkyl group, alkylaryl group, straight or branched alkyl group, (xi) —CHO so that R1 together with R3 provide the enol tautomer (a); OR R2 together with R3 form (xii) a pyrazole wherein (a) R4 is ═N—O-alkyl or ═N—O—H group, (b) the pyrazole is substituted with one of alkyl-OH group, alkyl ester group, alkyloxyalkyl group, branched alkyl group, and an amide and/or (c) the 2 position is substituted with a group selected from —OH and —O-hydrocarbyl (xiii) a heteroaryl ring to provide a compound of the formula (b); (II) R2 is selected from groups capable of forming a hydrogen bond, a sulphamate group, a phosphonate group, a thiophosphonate group, a sulphonate group and a sulphonamide group; and (III) R3 is selected from —OH, ═O, or a C(═O)—mimetic.

  提供了一个化合物的公式(I)，其中(I) R2选自(i)烷氧基烷基，(ii)腈基，且R2能够形成氢键，(iii)烷基芳基，其中芳基被取代，除了C1-10基团，(iv)烯基芳基，其中芳基被取代，(v)烷基杂芳基，其中杂芳基仅包含C和N，芳基被取代，除了甲基基团，(vi)烯基杂芳基，(vii) ═N—O-烷基或═N—O—H基团，(viii)支链烯基，(ix)烷基醇基团，(x)酰胺或烷基酰胺，其中(a)烷基酰胺的烷基是—CH2—或—Ch2Ch2—，(b)酰胺是二取代的和/或(c)酰胺被取代，至少有一个是烷基杂环基团，烯基杂环基团，烷基杂芳基，烯基杂芳基，杂芳基，烷基胺基，烷氧基烷基，烷基芳基，直链或支链烷基，(xi) —CHO，使得R1与R3提供烯醇互变异构体(a)；或R2与R3形成(xii)吡唑，其中(a)R4是═N—O-烷基或═N—O—H基团，(b)吡唑被取代，其中取代基是烷基-OH基团，烷基酯基团，烷氧基烷基，支链烷基和酰胺，和/或(c)2位被取代，所选的基团是—OH和—O-烃基，(xiii)杂芳环，以提供公式(b)的化合物；(II) R2选自能够形成氢键，磺酰胺基团，膦酸盐基团，硫代磷酸盐基团，磺酸盐基团和磺酰胺基团的基团；(III) R3选自—OH，═O或C(═O)-类似物。
• [DE] NEUE 2-SUBSTITUIERTE D-HOMO ESTRA-1,3,5(10)-TRIENE ALS INHIBITOREN DER 17ß-HYDROXYSTEROIDDEHYDROGENASE TYP 1<br/>[EN] NOVEL 2-SUBSTITUTED D-HOMO-ESTRA-1,3,5(10)-TRIENES AS INHIBITORS OF 17ß-HYDROXYSTEROID DEHYDROGENASE TYPE 1<br/>[FR] NOUVEAUX D-HOMO-ESTRA-1,3,5(10)-TRIENES 2-SUBSTITUES SERVANT D'INHIBITEURS DE LA 17ß-HYDROXYSTEROIDE-DESHYDROGENASE DE TYPE 1
  申请人：SCHERING AG

  公开号：WO2006003012A1

  公开（公告）日：2006-01-12

  Die Erfindung betrifft neue 2-substituierte D-Homo-Estra-1,3,5(10)-triene der allgemeinen Formel (I), worin R2 eine C1-C8-Alkyl, eine C1-C8-Alkyloxygruppe oder ein Halogenatom, R13 ein Wasserstoffatom oder eine Methylgruppe, R17 ein Wasserstoff- oder ein Fluoratom, bedeuten, sowie ihre pharmazeutisch annehmbaren Salze, deren Herstellung und Verwendung als Arzneimittel zur Prophylaxe und Therapie estrogenabhängiger Erkrankungen, die sich durch Hemmung der 17β-Hydroxysteroiddehydrogenase Typ 1 beeinflussen lassen.

  该发明涉及新的一般式（I）的2-取代D-Homo-Estra-1,3,5（10）-三烯，其中R2表示C1-C8烷基，C1-C8烷氧基或卤素原子，R13表示氢原子或甲基基团，R17表示氢原子或氟原子，以及它们的药学上可接受的盐，其制备和用作药物预防和治疗雌激素依赖性疾病，可通过抑制17β-羟基类固醇脱氢酶1型来影响。
• Estrogen nucleus derivatives for use in the inhibition of sex steroid activity
  申请人：ENDORECHERCHE INC.

  公开号：EP0367576A2

  公开（公告）日：1990-05-09

  Novel derivatives of estrogenic nuclei, contain a side-chain substitution of the formula -R1[B-R2-]x L-G and may be used in pharmaceutical compositions as sex steroid activity inhibitors useful in the treatment of both androgen-related and estrogen-related diseases.

  雌激素核的新型衍生物，含有式-R1[B-R2-]x L-G的侧链取代物，可作为性类固醇活性抑制剂用于药物组合物中，可用于治疗与雄激素相关和与雌激素相关的疾病。
• 17beta-hydroxysteroid dehydrogenase inhibitors
  申请人：Sterix Limited

  公开号：EP2336146A1

  公开（公告）日：2011-06-22

  There is provided a compound of Formula I wherein (I) R1 is a selected from (i) an alkyloxyalkyl group (ii) a nitrile group, and wherein R2 is capable of forming a hydrogen bond (iii) alkylaryl group, wherein the aryl group is substituted by other than a C1-10 group (iv) alkenylaryl group wherein the aryl group is substituted (v) alkylheteroaryl group, wherein when heteroaryl group comprises only C and N in the ring, the aryl group is substituted by other than a methyl group (vi) alkenylheteroaryl group, (vii) =N-O-alkyl or =N-O-H group (viii) branched alkenyl (ix) alkyl-alcohol group (x) amide or alkylamide wherein (a) the alkyl of the alkylamide is - CH2- or -CH2CH2-, (b) the amide is di-substituted and/or (c) the amide is substituted with at least one of alkylheterocycle group, alkenylheterocycle group, alkylheteroaryl group, alkenylheteroaryl group, heteroaryl group, alkylamine group, alkyloxyalkyl group, alkylaryl group, straight or branched alkyl group, (xi) -CHO so that R1 together with R3 provide the enol tautomer OR R1 together with R3 form (xii) a pyrazole wherein (a) R4 is =N-O-alkyl or =N-O-H group, (b) the pyrazole is substituted with one of alkyl-OH group, alkyl ester group, alkyloxyalkyl group, branched alkyl group, and an amide and/or (c) the 2 position is substituted with a group selected from -OH and -O-hydrocarbyl (xiii) a heteroaryl ring to provide a compound of the formula (II) R2 is selected from groups capable of forming a hydrogen bond , a sulphamate group, a phosphonate group, a thiophosphonate group, a sulphonate group and a sulphonamide group; and (III)R3 is selected from -OH, =O, or a -C(=O)- mimetic

  提供了一种式 I 的化合物 其中(I)R1选自(i)烷氧基烷基(ii)腈基，其中R2能形成氢键(iii)烷芳基，其中芳基被C1-10基团以外的基团取代(iv)烯芳基，其中芳基被取代(v)烷基杂芳基，其中当杂芳基在环中仅包括C和N时，芳基被甲基以外的基团取代(vi)烯基杂芳基、(vii) =N-O-烷基或 =N-O-H-基团 (viii) 支链烯基 (ix) 烷醇基 (x) 酰胺或烷酰胺，其中 (a) 烷酰胺的烷基是-CH2-或-CH2CH2-，(b) 酰胺是二取代的和/或 (c) 酰胺被烷基杂环基团中的至少一个取代、烯基杂环基团、烷基杂芳基基团、烯基杂芳基基团、杂芳基基团、烷基胺基团、烷氧基烷基基团、烷芳基基团、直链或支链烷基基团中的至少一个被取代； (xi) -CHO，这样 R1 与 R3 一起提供烯醇同分异构体 (xii) 吡唑，其中 (a) R4 为 =N-O- 烷基或 =N-O-H 基团，(b) 吡唑被烷基-OH 基团、烷基酯基团、烷氧基烷基基团、支链烷基基团和酰胺中的一个基团取代，和/或 (c) 2 位被选自-OH 和-O-氢羰基的基团取代 (xiii) 杂芳基环，提供式中化合物 (II) R2 选自能形成氢键的基团、氨基磺酸基、膦酸基、硫代磷酸基、磺酸基和磺酰胺基； (III) R3 选自-OH、＝O 或-C(＝O)-模拟基。